Hlx Life Sciences are delighted to be partnering with MultiOmic Health on the hiring of their Director/Associate Director of Translational & Biomarker Research.
MultiOmic Health ("MOH") is developing a cutting-edge, data-centric platform to advance precision medicine for various chronic dysglycemia-associated complications and cardiorenal indications.
Since 2021, MOH has assembled specialized multi-omic and longitudinal clinical datasets from patients with chronic renal complications associated with dysglycemia.
Using these datasets, MOH has initiated several innovative preclinical programs aimed at specific subpopulations affected by diabetic kidney disease and other chronic renal conditions, characterized by dysregulated cellular processes that current drugs do not adequately address.
The company is drug modality agnostic, with a philosophy of selecting the most practical and effective modality for each target.
Accordingly, all wet science work is performed by CROs or biopharma collaborators coordinated by MOH's in-house specialists.
MOH is seeking to recruit a Director or Associate Director of Translational & Biomarker Research , a role reporting to the company's Chief Operating Officer.
Seeking an experienced leader to drive patient cohort research and precision medicine R&D.
Responsibilities include establishing data partnerships with scientific collaborators, designing patient cohorts, and coordinating cross-functional drug target prioritization and biomarker development.
The role also entails managing validation programs for drug targets and biomarkers and advancing diagnostic development efforts.
This individual will work closely with internal teams and external partners to research and implement biomarker models derived from patient data, and oversee diagnostic development programs, including partnerships to develop and commercialize companion diagnostics for new therapeutics.
Experience Desired Extensive experience in interpreting omics data — genetics, epigenetics, transcriptomics, proteomics, metabolomics, etc.
— and linking this data to biological pathways and clinical phenotypes.
Familiarity with key issues and scientific disciplines in biomarker discovery and companion diagnostics development.
Proven track record, with involvement in at least two biomarker discovery and/or companion diagnostic development projects.
Some experience in cardiometabolic and/or renal diseases preferred.
Academic background in biology, biochemistry, or biotechnology.
Preferred but not essential: Experience in a smaller, resource-constrained organization (e.g., biotech, mid-sized pharma, integrated drug discovery CRO) rather than solely in large pharma.
If this role sounds well matched to what you might be looking for, please either apply including your CV or contact Hlx Life Sciences lead on this search, Alex Hiscock.